Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

MLA

Cairncross, J.Gregory, et al. “Benefit from Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated with Mutation of IDH.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 32, no. 8, Mar. 2014, pp. 783–90. EBSCOhost, https://doi.org/10.1200/JCO.2013.49.3726.

APA

Cairncross, J. G., Wang, M., Jenkins, R. B., Shaw, E. G., Giannini, C., Brachman, D. G., Buckner, J. C., Fink, K. L., Souhami, L., Laperriere, N. J., Huse, J. T., Mehta, M. P., & Curran, W. J., Jr. (2014). Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 32(8), 783–790. https://doi.org/10.1200/JCO.2013.49.3726

Chicago

Cairncross, J Gregory, Meihua Wang, Robert B Jenkins, Edward G Shaw, Caterina Giannini, David G Brachman, Jan C Buckner, et al. 2014. “Benefit from Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated with Mutation of IDH.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 32 (8): 783–90. doi:10.1200/JCO.2013.49.3726.